Effects of ACE inhibitor and AT 1 blocker on dystrophin-related proteins and calpain in failing heart

Cardiovascular Research

Volumn 65, Issue 2, 2005, Pages 356-365

  Takahashi, Masaya ^a   Tanonaka, Kouichi ^a   Yoshida, Hiroyuki ^a   Oikawa, Ryo ^a   Koshimizu, Miki ^a   Daicho, Takuya ^a   Toyo Oka, Teruhiko ^b   Takeo, Satoshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Candesartan; Dystrophin; Experimental; Heart; Heart failure; Organ and subcellular; Pathophysiology; Sarcoglycan; Trandolapril

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALPAIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SARCOGLYCAN; TRANDOLAPRIL; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART FAILURE; HEART LEFT VENTRICLE; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; CALPAIN; CYTOSOL; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; INDOLES; MALE; MODELS, ANIMAL; MYOCARDIUM; PROTEIN ISOFORMS; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOGLYCANS; TETRAZOLES;

EID: 11444264720     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.09.022     Document Type: Article

References (28)

1. E. Ozawa, S. Noguchi, Y. Mizuno, Y. Hagiwara, and M. Yoshida From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy Muscle Nerve 21 1998 421 438
2. M. Vatta, S.J. Stetson, A. Prez-Verdia, M.L. Entman, G.P. Noon, and G. Torre-Aminoe Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy Lancet 359 2002 936 941
3. L.M. Kunkel Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy Nature 11 1986 73 77
4. P. Melacini, M. Fanin, D.J. Duggan, M.P. Freda, A. Berardinelli, and G.A. Danieli Heart involvement in muscular dystrophies due to sarcoglycan gene mutations Muscle Nerve 22 1999 473 479
5. T. Kawada, M. Nakazawa, S. Nakauchi, K. Yamazaki, R. Shimamoto, and M. Urabe Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters Proc. Natl. Acad. Sci. U. S. A. 99 2002 901 906
6. C. Badorff, G.-H. Lee, B.J. Lamphear, M.E. Martone, K.P. Campbell, and R.E. Rhoads Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy Nat. Med. 5 1999 320 326
7. H. Yoshida, M. Takahashi, M. Koshimizu, K. Tanonaka, R. Oikawa, and T. Toyo-oka Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction Cardiovasc. Res. 59 2003 419 427
8. A. Sanbe, K. Tanonaka, Y. Hanaoka, T. Katoh, and S. Takeo Regional energy metabolism of failing heart following myocardial infarction J. Mol. Cell. Cardiol. 25 1993 995 1013
9. H. Yoshida, K. Tanonaka, Y. Miyamoto, T. Abe, M. Takahashi, and M.B. Anand-Srivastava Characterization of cardiac myocyte and tissue β-adrenergic signal transduction in rats with heart failure Cardiovasc. Res. 50 2001 34 45
10. K. Tanonaka, K. Furuhama, H. Yoshida, K. Kakuta, Y. Miyamoto, and S. Takeo Protective effect of heat shock protein 72 on the contractile function of the perfused failing heart Am. J. Physiol. 281 2001 H215 H222
11. A. Sanbe, K. Tanonaka, R. Kobayashi, and S. Takeo Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction J. Mol. Cell. Cardiol. 27 1995 2209 2222
12. H. Yoshida, M. Takahashi, K. Tanonaka, T. Maki, Y. Nasa, and S. Takeo Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure Br. J. Pharmacol. 134 2001 150 160
13. T. Toyo-oka, T. Shimizu, and T. Masaki Inhibition of proteolytic activity of calcium activated neutral protease by leupeptin and antipain Biochem. Biophys. Res. Commun. 82 1978 484 491
14. S. Sandmann, M. Yu, and T. Unger Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT1 and AT2 receptor antagonists and ACE inhibitor Br. J. Pharmacol. 132 2001 767 777
15. A. Hanatani, M. Yoshiyama, K. Takeuchi, S. Kim, K. Nakayama, and T. Omura Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infracted rats Jpn. J. Pharmacol. 78 1998 45 54
16. K.K. McMahon Developmental changes of the G proteins-muscarinic cholinergic receptor interactions in rat heart J. Pharmacol. Exp. Ther. 251 1989 372 377
17. H. Hanada, T. Yoshida, Y. Pan, Y. Iwata, M. Nishimura, and M. Shigekawa mRNA expression and cDNA sequences of β- and γ-sarcoglycans are normal in cardiomyopathic hamster heart Biol. Pharm. Bull. 20 1997 134 137
18. S. Noguchi, E. Wakabayashi, M. Imamura, M. Yoshida, and E. Ozawa Developmental expression of sarcoglycan gene products in cultured myocytes Biochem. Biophys. Res. Commun. 262 1999 88 93
19. J.-I. Kambayashi, and M. Sakon Calcium-dependent proteases and their inhibitors in human platelets J. Hawiger Platelets: Receptors, Adhesion, Secretion Methods in Enzymology vol. 169 1989 Academic Press San Diego, CA 442 454
20. L. Waxman Calcium-activated proteases in mammalian tissues L. Lorand Methods in Enzymology vol. 80 1981 Academic Press New York, NY 664 680
21. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N. Engl. J. Med. 327 1992 669 677
22. R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, and J. Probstfield Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVED) pilot study. The RESOLVD Pilot Study Investigators Circulation 100 1997 1056 1064
23. L. Kober, C. Torp-Pedersen, J.E. Carlsen, H. Bagger, P. Eliasen, and K. Lyngborg A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N. Engl. J. Med. 333 1995 1670 1676
24. B. Pitt, R. Segal, F.A. Martinez, G. Meurers, A. Cowley, and I. Thomas Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349 1997 747 752
25. F.S. Kraly, and R. Corneilson Angiotensin II mediates drinking elicited by eating in the rat Am. J. Physiol. 258 1990 R436 R442
26. M. Böhm, O. Zolk, M. Flesch, F. Schiffer, P. Schnabel, and J.-P. Stasch Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac β-adrenergic signal transduction Hypertension 31 1998 747 754
27. K. Suzuki, S. Imajoh, Y. Emori, H. Kawasaki, Y. Minami, and S. Ohno Calcium activated neutral protease and its endogenous inhibitor: activation at the cell membrane and biological function FEBS Lett. 220 1987 271 277
28. T. Toyo-oka, T. Kawada, J. Nakata, H. Xie, M. Urabe, and F. Masui Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction Proc. Natl. Acad. Sci. U. S. A. 101 2004 7381 7385